24/7 Market News- Novocure Reports FDA Approvel of Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer

October 16, 2024

DENVER, Colo., Oct 16, 2024 (247marketnews.com)- Novocure (NASDAQ: NVCR) reported that the U.S. Food and Drug Administration (FDA) approved its Optune Lua wearable treatment for concurrent use with PD-1/PD-L1 inhibitors or docetaxel, for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have progressed on or after a platinum-based regimen.

Optune Lua delivers Tumor Treating Fields (TTFields) by exerting physical forces on the electrically charged components of dividing cancer cells, resulting in cell death, and the pivotal Phase 3 LUNAR trial results represent the first substantial improvement in median overall survival in more than 8 years for this patient population.

Asaf Danziger, Novocure’s CEO, commented, “Novocure is committed to extending survival in some of the most aggressive and difficult to treat cancers. The approval of Optune Lua brings a new and urgently needed option for people with metastatic NSCLC who have progressed while on or after platinum-based chemotherapy.

“We are grateful to the patients, caregivers, investigators and healthcare providers who supported the clinical trials that led to this approval.”

“There have been a number of important advances in first-line treatment for NSCLC, but this is an aggressive disease, and most patients will develop progression, with limited effective treatment options in second line and beyond,” said Ticiana Leal, MD, Associate Professor and Director of the Thoracic Oncology Program at the Winship Cancer Institute of Emory University School of Medicine and primary investigator of the LUNAR study. “The overall survival results we observed with Optune Lua in the LUNAR study mark the first substantial improvement in more than 8 years in this patient population which, when combined with Optune Lua’s lack of systemic toxicity, make this a compelling development for many patients and their physicians who need better treatment options for this advanced disease.”

Danielle Hicks, GO2 for Lung Cancer Chief Patient Officer, added, “The fight against lung cancer is always evolving, and the number of people affected by this disease is underappreciated. That is why Novocure’s commitment to advancing treatment is exciting for the whole lung cancer community.”

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (NVCR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.